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Zinc and platelet
membrane microviscosity
in Alzheimer's disease
The in vivo effect of zinc on platelet
membranes and cognition
Felix C V Potocnik, Susan J van Rensburg,
Camn Pari<, Joshua J F Taljaard, Robin A Emsley
Objectives. To investigate the effects of oral zinc
supplementation on: (I) plasma zinc concentrations; (il)
platelet membrane microviscosity in vivo; and (iil) cognitive
function of Alzheimer's disease (AD) patients.
Design. An open-labelled pilot study.
Setting. University of Ste/lenbosch Medical School and
Stikland Hospital.
Subjects. Six volunteer AD patients.
Outcome measures. Plasma zinc levels, platelet
membrane microviscosity and cognition (MMSE and
ADAS-cog tests).
Results. Oral zinc supplementation (30 mglday) did not
increase plasma zinc levels significantly, but signfficantly
increased platelet membrane microviscosity (P = 0.02; 6
patients). Four patients. who underwent 12 months of
evaluation, showed modest cognitive improvement on
psychomebic testing (Mini·Mental State Examination and
the cognitive portion of the Alzheimer's Disease
Assessment scale scores).
Conclusions. While earlier literature promoted the use of
zinc in AD patients, a recent study has contradicted this
and implicated zinc in the aetiology of Alzheimer's
disease. On the basis of the above resutts, it may be
premature to single out zinc as a causal agent in AD.
S Afr Med J 1997; 87: 1116-1119.
Recent years have led to the discovery of several genetic
components implicated in the aetiology of Alzheimer's
disease (AD).' Environmental factors, however, are believed
to accelerate disease expression in genetically susceptible
individuals, as is evidenced by the fact that in monozygotic
twins, age of onset of AD may differ by as much as 15
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years, or that the twins may even be discordant for the
disease.2 This contrasts with Huntington's disease, in which
no discordancy has been reportecP The discovery of
environmental factors responsible for AD in vulnerable
individuals and protection against them could conceivably
alter the date of onset, severity and course of the disease.
A de/ay in the onset of AD by only 5 years would halve the
prevalence of the illness, resulting in enormous cost-savings
and preventing much human misery.3
Atthough AD is seen as a disease of the brain, there is
mounting evidence that peripheral cells are also affected.
In 1987 Zubenko et al.' discovereclreduced platelet
membrane microviscosity (reciprocal of membrane fluidity) in
55% of AD patients, as well as 8% of healthy control
subjects. Because this abnormality in platelet membrane
microviscosity occurred in only half of all AD patients, it could
not be used as a diagnostic marker for AD. The observation
that a small proportion of healthy control subjects as well as
some healthy firsHJegree relatives had lowered platelet
membrane microviscosi~ has led to speculation about the
susceptibility of these individuals to AD in later Hfe. A long-
tenn prospective study, however, would be required to
establish whether this is indeed the case. Other authors have
confirmed the presence of decreased platelet membrane
microviscosity in AD patients.&.1
It has recently come to light that free radical-derived lipid
peroxidation decreases platelet membrane microviscosity,
and that high levels of ascorbic acid eliminate the
membrane damage in the in vitro system.tI Zinc also
decreases lipid peroxidation in vitro.' Jeandel et al.'O found
that the blood concentrations of several free-radical
scavengers that protect against free radical damage,
including ascorbate and zinc, were significantly lower in AD
patients than in control subjects.
Metal ions alter platelet membrane microviscosity by
binding to charged headgroups of membrane
phospholipids.1I Van Rensburg et al. 12 demonstrated that
aluminium ions decreased while zinc ions increased the
microviscosity of platelet membranes in vitro.
A role for zinc in dementia is suggested by the fact that
reduced levels of zinc are found in both plasma'o and brain
tissue of AD patients, especially in the hippocampus. 13 The
highest concentration of zinc in the brain is found in the
hippocampal mossy fibres,14 localised in excitatory boutons,
where zinc is co-released with glutamate during neuronal
activity in the form of dense synaptic vesicles. l £ Westbrook
and Mayer15 suggested that zinc may regulate both excitatory
and inhibitory synaptic transmission in the hippocampus and
that zinc may therefore play an important role in long-term
potentiation, Le. in the processing of memory formation.
In 1992 a hypothesis was put forward that zinc deficiency
in the hippocampus may contribute to the pathogenesis of
neurofibrillary tangles and that this may be prevented by
treatment with zinc compounds. 1&Recently, Bush et al. 17
contested this line of thinking by postulating that zinc
actually contributed to AD by precipitating ~-amyloid. This
experiment essentially consisted of adding zinc to a-amyloid
in a test tube and finding the latter aggregated.
While Mantyh et al.'8 showed that aluminium and iron, as
well as zinc, in high concentrations were capable of
aggregating a-amyloid, Bush et al. 17 also reported a negative
effect of zinc on the cognition of a small sample (the number
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of patients and the dosage of zinc administered were not
published) of AD patients within a few days of starting
supplementation.'7 These findings did not concur with the
results of our own work in progress at the time.
An open-labelled study was undertaken to investigate the
in vivo effects of oral zinc supplementation on: (I) plasma zinc
concentration; (iI) platelet membrane microviscosity; and (iil)
cognitive function of AD patients over a l-year period.
Patients and methods
Six patients (4 men and 2 women; mean age 63.6 years,
range 51 - 79) were diagnosed with AD according to the
definition given by the National Institute of Neurological and
Communicative Disorders and Stroke - Alzheimer's Disease
and Related Disorders Association (NINCDS-ADRDA)" work
group and the criteria in the DSM-II/-R,20 as described
previously.7 The mean Mini-Mental State Examination
(MMSEY' score for the patients before supplementation was
16 out of 30 (range 12 - 21). The study was approved by the
Ethics Committee of the University of Stellenbosch.
The 6 AD patients were given oral zinc in the form of zinc
chelated with methionine (15 mg twice daily). Plasma zinc
levels and platelet membrane microviscosity were measured
before, during and after the supplementation period. The
patients acted as their own controls.
Plasma zinc levels were determined with a Varian Techtron
Model 1200 atomic absorption spectrophotometer. Platelet
membranes were isolated, and membrane microviscosity
(reciprocal of membrane flUidity) was determined by the
method of Zubenko et al.'
The cognitive functioning of 4 AD patients (2 men and 2
women; mean age 67.7 years, range 63 - 72; mean MMSE
18, range 14 - 21) was monitored over a l-year period by
the quarterly administration of a psychometric test battery
which included the MMS!?' and the cognitive portion of the
Alzheimer's Disease Assessment Scale (ADAS-eog).22 These
patients were receiving oral zinc chelated with methionine
(15 mg twice daily).
Results
In spite of oral zinc supplementation, the resulting plasma
zinc levels were variable, and even decreased in 2 instances
(Table I). Normal plasma zinc values range between 14 and
34 ~moVl.
In all 6 patients, the platelet membrane microviscosity
values increased to reach similar values within 1 - 3 months
(Patients A - F; Fig. 1). For the group, the increase was
statistically significant (P = 0.02; Wilcoxon rank test).
Increased platelet membrane microviscosity values were
sustained, provided zinc supplementation continued (results
not shown).
Following the initiation of zinc supplementation, all 4
patients showed a modest temporary peak in psychometric
performance at the 3-month mark, relative to their baseline
test scores on the same battery. This cognitive improvement
coincided with the caregivers' reports of improved day-to-
day functioning and was also reflected in the MMSE scores
(Fig. 2). For the MMSE, the highest score is 30, and the
Table I. Effects of oral zinc supplementation on plasma zinc
concentration {lJmol/l} in 6 patients with Alzheimer's disease
Plasma zinc (J.JmoVl)
Patient Baseline 1 month 3 months
A 11.5 14.4 15.4
B 14.5 15.2 18.8
C 13.0 20.2 15.4
0 12.6 13.6 13.8
E 14.3 11.4 13.6
F 20.6 17.5 18.0
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Fig. 1. Platelet membrane microviscosity of 6 patients (A - F)
receiving oral zinc supplementation (3D mg/day). In all patients,
microviscosity increased over a period of 3 months to reach
similar values. For the group, the increase was significant
(P = 0.2). The patients were their own controls.
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Fig. 2. Change in cognitive performance (MMSE) of 4 AD patients
receiving oral zinc supplementation for 12 months. Values
represent mean ± SEM. For the MMSE, the expected decline is
2.4 • 3 points per year.
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expected decline for AD patients is some 3 points per year
(range 2.4 - 4).n The MMSE decline for the 4 AD patients
after 1 year of zinc supplementation was less than expected
(Fig. 2).
For the ADAS-eog, the perfect score is 0, and in AD an
increase of some 7 - 9 points per year is to be expected.
Again, the decline in cognition of the 4 AD patients after
1 year of zinc supplementation was less than expected
(Fig.3).n
8
patients with AD. At the described dosages of zinc
supplementation, all our patients were cognitively better off
after 1 year than if they had not taken zinc. These results
are in agreement with those obtained by Van Rhijn et al.,:n
who showed that 15 AD patients receiving dietary
supplementation of zinc sulphate, sodium selenite and fatty
acids over a 20-week period showed significantly improved
performance on psychometric testing. The negative effect
observed by Bush et al. in his AD patients within a few days
of zinc supplementation (dosage not pUblished) may have
been due to aluminium, rather than zinc. As a general
principle, an addition of one metal to the body leads to the
redistribution of other metals. linc has been shown to cause
the release of aluminium from membranes l2 and, as
demonstrated previOUSly, aluminium in this free form would
have negative effects on several systems in the body,
causing nuclear damage and alteration of neurotransmitter
and enzyme functions.Z8 Higher levels of zinc would
compound this effect.
Furthermore, the very high levels of zinc found in the
hippocampus are enclosed in protective membranous
vesicles.l~ In vitro experiments would not account for this.
In 2 of the 6 patients receiving zinc supplementation, an
increase in libido occurred, necessitating the prescription of
cyproterone acetate. A rise in libido following zinc
supplementation has previously been noted in the
literature.29
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Fig. 3. Change in cognitive performance (ADAS-cog) of 4 AD
patients receiving oral zinc supplementation for 12 months. For
the ADAS-cog, an increase of 7 • 9 points is expected. Values
have been inverted to show decline in cognition, and represent
mean:i: SEM.
Discussion
Zinc supplementation unexpectedly did not result in higher
plasma zinc levels in all patients. The variable plasma zinc
levels found may have reflected either a defect in the
absorption of zinc (unlikely, see below) or immediate
redistribution of absorbed zinc into body stores.
The 6 AD patients who received oral zinc supplementation
displayed a steady increase in platelet membrane
microviscosity. This suggests that zinc plays an important
role in maintaining the patency of the microviscosity of
membranes in the body. This role could be structuraJ,2~ in
that zinc may bind to the charged headgroups of
phospholipids in membranes,i:5 or produce an atteration of
the phospholipid composition of the membranes. Driscoll
and Bettge~ found that dietary zinc deficiency in rats
caused a change in erythrocyte phospholipid composition.
Zinc may also protect platelet membranes from decreased
membrane microviscosity caused by lipid peroxidation,8
through the inhibition of free radical reactions.25
The fact that oral zinc supplementation had a positive
effect on platelet membrane microviscosity in the presence
of variable plasma zinc levels, indicates that the latter does
not reflect the zinc concentration present in these
membranes.
Though preliminary, the results counter the claims made
by Bush et al. 11 that zinc adversely affects the cognition of
Conclusion
Zinc supplementation corrected the membrane
microviscosity of platelets in a sample of 6 AD patients.
A further ongoing study of 4 patients showed that zinc
supplementation resulted in a modest temporary
improvement in the cognition of all of these patients, as
observed on psychometric testing. This is at variance with
Bush et aJ.'s17 report of rapid cognitive deterioration in AD
patients receiving zinc supplementation. The latter effect
may have been dose-related, thus altering the distribution of
and upsetting the balance of other metals in the body, with
negative consequences. We feel that it may be premature to
single out zinc as a causal agent in AD.
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Thyroid dysfunction in the
elderly
G M M Muller, N S Levitl, S J Louw
Objectives. To determine the prevalence of thyroid
dysfunction in institutionalised elderly people in Cape
Town and to assess the usefulness of an abnormal
thyroid-stimulating hormone (TSH) concentration as a
screening test in this group.
Design. Cross-sectional survey.
Setting. Four old-age homes in Cape Town.
Subjects. Old-age home residents aged 60 years and
over.
Outcome measures. Serum concentrations of TSH, tree
thyroxine and free tri-iodothyronine.
Results. Serum TSH estimations were performed on 658
participants, and were abnormal in 103 (15.6%) - 41
(6.2%) being elevated (> 5.0 ~U/ml) and 62 (9.4%) being
low « 0.4 IJU/ml). There were 3 newly diagnosed cases of
hyperthyroidism and 7 of hypothyroidism. Subclinical
disease was diagnosed in 40 subjects. The overall
prevalence of thyroid dysfunction in this population was
11.2%. In 22 (3.4%) this had previously been recognised,
while in 50 (7.8%) the dysfunction was newly diagnosed
by the current survey. The positive predictive value of a
TSH concentration> 20 jJU/ml in predicting
hypothyroidism is 67%, while it will predict 100% of cases
of subclinical hypothyroidism. A TSH concentration
< 0.1 ~U/ml will predict 23% of cases of hyperthyroidism,
but 81 % of cases of subclinical disease.
Conclusions. The prevalence of thyroid dysfunction in
institutionalised elderly people in Cape Town is similar to
that reported for elderly people in other centres. Thyroid
dysfunction had not previously been recognised in
approximately two-thirds of the subjects in this study. The
serum TSH concentration is a reliable screening test for
thyroid dysfunction in the elderly, but is less useful if used
to identify biochemical thyroid disease. An elevated TSH
concentration is a better predictor of thyroid dysfunction
in the elderly than a depressed TSH concentration.
S Afr Med J 1997: 87: 1119-1123.
Thyroid disease may manifest atypically in the elderly,
leading to difficulties with clinical diagnosis. I .2 There are well
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